Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2025 08:00 ET | Source: Genmab A/S

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Media ReleaseCOPENHAGEN, Denmark; March 27, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in JapanApproval is...
March 25, 2025 17:28 ET | Source: Genmab A/S

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock...
March 21, 2025 23:29 ET | Source: Genmab A/S

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will...
March 17, 2025 12:19 ET | Source: Genmab A/S

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed...
March 12, 2025 14:19 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
March 12, 2025 14:13 ET | Source: Genmab A/S

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company AnnouncementCOPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 12, 2025, the Company’s Board of Directors met to...
March 12, 2025 10:23 ET | Source: Genmab A/S

Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approvedDischarge was given to the Board of Directors and the Executive Management...
March 10, 2025 10:13 ET | Source: Genmab A/S

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not...
March 04, 2025 11:58 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
February 28, 2025 16:04 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right